Literature DB >> 15859931

Middle East Society for Organ Transplantation (MESOT) Transplant Registry.

Marwan A Masri1, Mehmet A Haberal, Faissal A M Shaheen, Antoine Stephan, Ahad J Ghods, Muhamed Al-Rohani, Mustafa Al Mousawi, Nabil Mohsin, Taieb Ben Abdallah, Adel Bakr, Adibul Hasan Rizvi.   

Abstract

During the seventies, sporadic renal transplants were performed in few MESOT-region countries, mainly Turkey, Iran, Egypt, and Lebanon. Since the introduction of cyclosporine in the early eighties, transplantation has become the preferred therapeutic modality for end-stage renal failure. In 1986, the Islamic theologians (Al Aloma) issued what became known as the Amman declaration, in which they accepted brain death and retrieval and transplantation of organs from living and cadaveric donors. Based on this and similar declarations, all Middle Eastern countries except Egypt passed laws that allow cadaveric transplantation and regulate live donations. Iran, Turkey, Saudi Arabia, Kuwait, Tunisia, Jordan, and Lebanon all have current active cadaveric programs and perform liver, heart, pancreas, and lung transplants. More than 5088 renal transplants/year are performed in the region with Iran leading with 1600. The cumulative number of renal transplant patients is now nearly 60,000. With a 2003 population of 600,682,175, the rate/million for renal transplantation in the MESOT region is a mere 9/million. Rates of renal transplantation range from 31/million in some countries to 0 in others. The major obstacle in establishing an accurate number of transplants is "tourist transplantation," in which the same transplanted patients are registered in different countries. Although cadaveric programs have been active for more than 10 years, live-related and nonrelated transplants account for nearly 85% of the total transplants. The data presented were collected from MESOT representatives in the region and from publications. For proper compilation of the registry, a format is being proposed that will be presented at the Congress for review and adaptation. Even with the limited resources in the region, immunosuppressive drugs for induction and maintenance therapy are available and are used. Costs for transplantation and immunosuppressive therapy are either totally or heavily supported by governmental agencies.

Entities:  

Mesh:

Year:  2004        PMID: 15859931

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.945


  6 in total

1.  Short history about renal transplantation program in Iran and the world: Special focus on world kidney day.

Authors:  Hamid Tayebi Khosroshahi
Journal:  J Nephropathol       Date:  2012-04-05

Review 2.  Dialysis-treated end-stage kidney disease in Libya: epidemiology and risk factors.

Authors:  Fathea Abobker Goleg; Norella Chiew-Tong Kong; Ramesh Sahathevan
Journal:  Int Urol Nephrol       Date:  2014-03-27       Impact factor: 2.370

3.  Brain-dead patients are not cadavers: the need to revise the definition of death in Muslim communities.

Authors:  Mohamed Y Rady; Joseph L Verheijde
Journal:  HEC Forum       Date:  2013-03

4.  Reasons for unwillingness of libyans to donate organs after death.

Authors:  Wa Alashek; Ef Ehtuish; A Elhabashi; W Emberish; A Mishra
Journal:  Libyan J Med       Date:  2009-09-01       Impact factor: 1.657

5.  Two-year experience of orthotopic liver transplantation in afzalipoor hospital, kerman, southeastern iran.

Authors:  M Dehghani; B Poorseidi; H Sattari; S Nikeghbalian; M J Zahedi; S M Seyyed-Mirzaei; M Shafiei; M Vahedian; S A Malek-Hosseini
Journal:  Int J Organ Transplant Med       Date:  2012

Review 6.  Challenges of pancreas transplantation in developing countries, exploring the Turkey example.

Authors:  Sanem Guler Cimen; Sertac Cimen; Nicos Kessaris; Eyup Kahveci; Acar Tuzuner
Journal:  World J Transplant       Date:  2019-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.